The FDA granted accelerated approval to Dizal Pharmaceutical's oral drug sunvozertinib (Zegfrovy) for adults with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The drug is the first approved targeted oral therapy for this genetic subset, based on overall response rates. Leadership at Dizal positions Zegfrovy as a potential safer and more effective alternative to Johnson & Johnson's Rybrevant, currently used as earlier-line therapy. The approval also includes a companion diagnostic cleared for identifying eligible patients.